Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2475-2025

STA-Liquid Anti-Xa 8. Recall

STA-Liquid Anti-Xa 8. Model/Catalog Number: 00322US. The STA - Liquid Anti-Xa kits are intended for use with STA-R, STA Compact and STA Satellite analyzers, for the quantitative determination of the plasma levels of unfractionated (UFH) and low molecular weight (LMWH) heparins by measuring their anti-Xa activity on antithrombin in a competitive assay using a synthetic chromogenic substrate.

FDA recall Class II

Ongoing

FDA lists this Class II recall for STA-Liquid Anti-Xa 8.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2475-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jul 21, 2025
FDA report date
Sep 3, 2025
Quantity in commerce
126,200 units (125,900 US)
Distribution
See key details
FDA cause
Mixed-up of materials/components

What is being recalled?

STA-Liquid Anti-Xa 8. Model/Catalog Number: 00322US. The STA - Liquid Anti-Xa kits are intended for use with STA-R, STA Compact and STA Satellite analyzers, for the quantitative determination of the plasma levels of unfractionated (UFH) and low molecular weight (LMWH) heparins by measuring their anti-Xa activity on antithrombin in a competitive assay using a synthetic chromogenic substrate.

Affected model & UDI checker

Search the exact identifiers published for Z-2475-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
00322USSTA-Liquid Anti-Xa 8.Check source noticeNot specified
Not specifiedSTA-Liquid Anti-Xa 8.Check source notice03607450011791
FDA code information

Model/Catalog Number: 00322US. UDI-DI: 03607450011791

View the original FDA recall notice

Why was this product recalled?

Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Diagnostica Stago, Inc. take?

Diagnostica Stago notified consignees on about 07/21/2025 via emailed letter titled URGENT: MEDICAL DEVICE RECALL (CORRECTION). Consignees were instructed to temporarily systematically run a quality control just before a batch of UFH or LMWH, if you run STA-LIQUID ANTI-Xa in UFH and LMWH applications on your STA SATELLITE analyzer. This request is being asked while Stago works to develop a permanent solution for the analyzer. Consignees were also requested to complete and return the Acknowledgement Form and to notify customers if affected units were transferred or further distributed.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology